Previous studies revealed that in B-ALL, CD133 expression is significantly correlated with a higher resistance to chemotherapy and is associated with a tendency toward poorer outcomes, a higher incidence of relapse, and death, as well as higher complete remission (CR) rates in CD133-negative ALL cases [22]. This evidence concerns the gene PROM1 and acute lymphoblastic leukemia.